Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report.

Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Studies show that it is an effective and well-tolerated treatment for attention-deficit hyperactivity disorder (ADHD). A number of reports suggest that ADHD may have a causal influence on the development of substance use disorders. The authors describe the use of moclobemide in a 27-year-old patient with comorbid opiate addiction and ADHD (residual type). The positive clinical response shown suggests that moclobemide may have a particular interest in the treatment of drug-dependent patients with current ADHD.